Company Filing History:
Years Active: 2007
Title: Michael Bernatowicz: Innovator in Diabetes Treatment
Introduction
Michael Bernatowicz is a notable inventor based in Princeton, NJ (US). He has made significant contributions to the field of diabetes treatment through his innovative research and development of peptide mimics.
Latest Patents
Bernatowicz holds 2 patents related to human glucagon-like peptide-1 (GLP-1) mimics. His latest patents focus on the development of novel GLP-1 peptide mimics that replicate the biological activity of the native GLP-1 peptide. These innovations are aimed at treating or preventing diseases associated with GLP activity. The chemically modified peptides not only stimulate insulin secretion in type II diabetics but also produce other beneficial insulinotropic responses. Furthermore, these synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage, making them ideal candidates for oral or parenteral administration.
Career Highlights
Michael Bernatowicz is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research in diabetes treatment. His work has positioned him as a key figure in the pharmaceutical industry, particularly in the development of therapeutic solutions for diabetes.
Collaborations
Throughout his career, Bernatowicz has collaborated with esteemed colleagues such as Sesha Iyer Natarajan and Claudio Mapelli. These collaborations have further enriched his research and contributed to the success of his innovative projects.
Conclusion
Michael Bernatowicz is a prominent inventor whose work in developing GLP-1 mimics has the potential to transform diabetes treatment. His contributions to the field highlight the importance of innovation in addressing critical health challenges.